---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Special populations"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Special populations. Topics: Himalayas-1 protocol: age, performance status, and organ function; Himalayas-1 protocol exclusion: brain metastases; Himalayas-1 protocol exclusion: cardiovascular disease, recent radiotherapy, and gastrointestinal disease; Phase 1b protocol exclusion: cardiac disease; 6 further topics. 10 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/special-populations"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Himalayas-1 protocol: age, performance status, and organ function

> “Male patients aged ≥18 years”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1”
> “Adequate organ function”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-2"></a>

### Himalayas-1 protocol exclusion: brain metastases

> “Known or suspected brain metastasis or active leptomeningeal disease”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-3"></a>

### Himalayas-1 protocol exclusion: cardiovascular disease, recent radiotherapy, and gastrointestinal disease

> “Clinically significant cardiovascular disease”
> “Radiotherapy within 2 weeks before randomization”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery are excluded”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-4"></a>

### Phase 1b protocol exclusion: cardiac disease

> “History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-5"></a>

### Phase 1b protocol exclusion: viral infection

> “Known, symptomatic human immunodeficiency virus (HIV) infection”
> “Active symptomatic Hepatitis B or C infection; patients with well controlled disease are eligible”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-6"></a>

### Phase 1b protocol exclusion: malabsorption and central nervous system metastases

> “Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, short gut syndrome, etc) or other malabsorption syndromes that would reasonably impact drug absorption per investigator judgement”
> “History or presence of CNS metastases, unless previously treated and stable”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-7"></a>

### Renal impairment: darolutamide, the combination partner

> “For patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m2) not receiving hemodialysis, the recommended dosage of NUBEQA is 300 mg twice daily”
> “No dose reduction is needed for patients with mild or moderate renal impairment (eGFR 30-89 mL/min/1.73 m2). The effect of end stage renal disease (eGFR ≤15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

### Hepatic impairment: darolutamide, the combination partner

> “For patients with moderate hepatic impairment (Child-Pugh Class B), the recommended dosage of NUBEQA is 300 mg twice daily”
> “No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-9"></a>

### Geriatric use: darolutamide, the combination partner

> “Of the 954 patients who received NUBEQA in ARAMIS, 88% of patients were 65 years and over, and 49% were 75 years and over.”
> “No overall differences in safety or efficacy were observed between these patients and younger patients in both studies.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-10"></a>

### Males of reproductive potential: darolutamide, the combination partner

> “Based on the mechanism of action, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of NUBEQA”
> “Based on animal studies, NUBEQA may impair fertility in males of reproductive potential”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
